



## **Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022**

November 08, 2022 06:00 AM Eastern Standard Time

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2022 annual general meeting of shareholders at its London office located at 4T.07, 17 Hanover Square, Mayfair London, England W1S 1BN at 12:00 noon London Time on December 21, 2022 (7:00 a.m. Eastern Standard Time on December 21, 2022 / 12:00 p.m. Greenwich Mean Time on December 21, 2022 / 1:00 p.m. Central European Time on December 21, 2022).

Shareholders of record as of October 14, 2022 are entitled to receive notice of and vote at the annual general meeting. Aptorum filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended December 31, 2021, with the U.S. Securities and Exchange Commission (the "SEC") on April 29, 2022. Aptorum Group's annual report on Form 20-F can be accessed in the investor section of Aptorum's website at [www.aptorumgroup.com](http://www.aptorumgroup.com), as well as on the SEC's website at [www.sec.gov](http://www.sec.gov). Shareholders may request a meeting notice, proxy card or hard copy of the annual report on Form 20-F, free of charge, by contacting [investor.relations@aptorumgroup.com](mailto:investor.relations@aptorumgroup.com).

### **About Aptorum Group**

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases. Aptorum has completed two phase I clinical trials for its ALS-4 (MRSA) and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell<sup>®</sup> nutraceutical (menopause). The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore's Agency for Science, Technology and Research.

For more information about the Company, please visit [www.aptorumgroup.com](http://www.aptorumgroup.com).

### **Disclaimer and Forward-Looking Statements**

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020.

As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided “as is” without any representation or warranty of any kind.

## Contacts

Aptorum Group Limited

Investor Relations Department

[investor.relations@aptorumgroup.com](mailto:investor.relations@aptorumgroup.com)

+44 20 80929299

Redchip – Financial Communications United States

Investor relations

Craig Brelsford

[craig@redchip.com](mailto:craig@redchip.com)

+1 407 571 0902

Actifin – Financial Communications Europe

Investor relations

Ghislaine Gasparetto

[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)

+33 1 56 88 11 22